Joseph Mikhael, MD, from the Mayo Clinic, Phoenix, AZ, USA, provides us with an insight into the high efficacy of isatuximab, an anti-CD38 monoclonal antibody, in treating patients with heavily relapsed multiple myeloma (MM), who are eligible for treatment with pomalidomide, as tested in a Phase I trial. He also describes challenge associated with this form of therapy, namely the significantly increased degree of leukopenia in patients undergoing a combination of isatuximab and pomalidomide and concludes with a note on how it is possible to control these side effects. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.